A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial

Srdan Verstovsek; Moshe Talpaz; Martha Wadleigh; Alessandro Isidori; Peter te Boekhorst; Michael R. Savona; Prithviraj Bose; Olga Pozdnyakova; Ruben Mesa; Tarec C. El-Galaly; Jennifer O'Sullivan; Katia Gamel; Brian Higgins; Sudhakar Katakam; Boyan Todorov; Kerstin Trunzer; Claire N. Harrison

doi:10.3324/haematol.2023.284410

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial

Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, Alessandro Isidori, Peter te Boekhorst, Michael R. Savona, Prithviraj Bose, Olga Pozdnyakova, Ruben Mesa, Tarec C. El-Galaly, Jennifer O'Sullivan, Katia Gamel, Brian Higgins, Sudhakar Katakam, Boyan Todorov, Kerstin Trunzer, Claire N. Harrison^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

Abstract

Not available.

Originalsprog	Engelsk
Tidsskrift	Haematologica
Antal sider	23
ISSN	0390-6078
DOI	https://doi.org/10.3324/haematol.2023.284410
Status	E-pub ahead of print - 25 jan. 2024

Adgang til dokumentet

10.3324/haematol.2023.284410Licens: CC BY 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Verstovsek, S., Talpaz, M., Wadleigh, M., Isidori, A., te Boekhorst, P., Savona, M. R., Bose, P., Pozdnyakova, O., Mesa, R., El-Galaly, T. C., O'Sullivan, J., Gamel, K., Higgins, B., Katakam, S., Todorov, B., Trunzer, K., & Harrison, C. N. (2024). A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial. Haematologica. Advance online publication. https://doi.org/10.3324/haematol.2023.284410

@article{20641f9e11e2497bb4cdb9df398b0790,

title = "A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial",

abstract = "Not available.",

author = "Srdan Verstovsek and Moshe Talpaz and Martha Wadleigh and Alessandro Isidori and {te Boekhorst}, Peter and Savona, {Michael R.} and Prithviraj Bose and Olga Pozdnyakova and Ruben Mesa and El-Galaly, {Tarec C.} and Jennifer O'Sullivan and Katia Gamel and Brian Higgins and Sudhakar Katakam and Boyan Todorov and Kerstin Trunzer and Harrison, {Claire N.}",

year = "2024",

month = jan,

day = "25",

doi = "10.3324/haematol.2023.284410",

language = "English",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

}

Verstovsek, S, Talpaz, M, Wadleigh, M, Isidori, A, te Boekhorst, P, Savona, MR, Bose, P, Pozdnyakova, O, Mesa, R, El-Galaly, TC, O'Sullivan, J, Gamel, K, Higgins, B, Katakam, S, Todorov, B, Trunzer, K & Harrison, CN 2024, 'A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial', Haematologica. https://doi.org/10.3324/haematol.2023.284410

TY - JOUR

T1 - A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial

AU - Verstovsek, Srdan

AU - Talpaz, Moshe

AU - Wadleigh, Martha

AU - Isidori, Alessandro

AU - te Boekhorst, Peter

AU - Savona, Michael R.

AU - Bose, Prithviraj

AU - Pozdnyakova, Olga

AU - Mesa, Ruben

AU - El-Galaly, Tarec C.

AU - O'Sullivan, Jennifer

AU - Gamel, Katia

AU - Higgins, Brian

AU - Katakam, Sudhakar

AU - Todorov, Boyan

AU - Trunzer, Kerstin

AU - Harrison, Claire N.

PY - 2024/1/25

Y1 - 2024/1/25

N2 - Not available.

AB - Not available.

U2 - 10.3324/haematol.2023.284410

DO - 10.3324/haematol.2023.284410

M3 - Comment/debate

C2 - 38268448

SN - 0390-6078

JO - Haematologica

JF - Haematologica

ER -

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial

Abstract

Adgang til dokumentet

AUB Link

Fingeraftryk

Citationsformater